about
Interleukin-6 blockade in ocular inflammatory diseasesAnti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.Proinflammatory cytokines and C-reactive protein in uveitis associated with Behçet's diseaseOxaliplatin-Related Ocular ToxicityUse of ultra-wide-field retinal imaging in the management of active Behçet retinal vasculitis.Adalimumab for the treatment of Behçet's disease: experience in 19 patients.Pars plana vitrectomy for vitreoretinal complications of Behçet uveitis.Current and future treatments for Behçet's uveitis: road to remission.Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema.C-reactive protein isoforms differentially affect outer blood-retinal barrier integrity and function.Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.Indirect supportive evidence for diagnosis of tuberculosis-related uveitis: from the tuberculin skin test to the new interferon gamma release assays.Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization.Bacillus Calmette-Guérin Infection and Cytotoxicity in the Retinal Pigment Epithelium.Regulatory T cell levels and cytokine production in active non-infectious uveitis: in-vitro effects of pharmacological treatment.Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients.Tocilizumab treatment for refractory uveitis-related cystoid macular edema.Cytokine profiling reveals decreased serum levels of CCL2 in active ocular toxoplasmosis.Clinical pattern of toxoplasmic retinochoroiditis in a Spanish referral center.Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.Uveitic macular oedema after treatment with vemurafenib.Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patientsCertolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular InflammationVasculopatía retiniana en el lupus eritematoso sistémico: caso de vasculitis lúpica y caso de oclusión venosa no vasculíticaTocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case reportTocilizumab treatment for recalcitrant uveitic macular edemaAdalimumab in Serpiginous ChoroiditisBehçet Disease-associated Uveitis Successfully Treated with GolimumabLATE SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN SUB-INTERNAL LIMITING MEMBRANE HEMORRHAGEUveítis asociadas a enfermedad desmielinizante del sistema nervioso centralCandida dubliniensis endophthalmitis in a HIV-infected intravenous drug abuserCirugía de vitrectomía para el tratamiento de las complicaciones vítreo-retinianas asociadas a pars planitisSíndrome del ocho y medioElevated Serum Immune Mediators and Subclinical Inflammation in HLA-A29-associated Birdshot ChorioretinopathyInterleukin-22 serum levels are elevated in active scleritisIn Response to: "Deuter CM, Zierhut M, Igney-Oertel A, et al. Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment"The role of inflammation in diabetic eye disease
P50
Q27011357-2DC2C598-32C2-4C8C-95EF-F70AE7F679CBQ33435733-57C96D38-304D-49BF-AFBF-90A3EA58FB7EQ33757440-E4563A93-9CBF-452B-B35B-6661ADE9A843Q33796694-2C5E13D0-5E36-496D-8F68-BA0317D4C53EQ34394155-ADA8EBF5-4A83-4E42-AD2E-0446C1B13F5DQ35191433-12B79CDC-61B1-4DBE-A094-79994614B2B0Q38020828-A2CBC270-B359-479A-8B2C-F2FBEC468997Q38052105-AE099801-B719-41C6-B8D9-43478ECA35B3Q38111308-D9604A6A-4273-4324-85E8-880582FDDE19Q38247504-83B3DA9F-5A8F-4C81-B1AE-4DBCB4F3446EQ38724929-1EC759C2-08DD-425B-9624-17551E5D87B4Q39384442-E16DD1CE-852F-4551-96B9-367008215C91Q40067200-A2D20E05-70CC-45EC-B783-6D7C7D22A5FCQ40257214-1BA21BB6-658B-41D5-9964-51C95AD6EFFBQ40397517-EF50F1CD-8C60-41A8-9FC4-E46132A3B969Q41685086-6E42FDFB-D24A-4780-8137-E1051D18A820Q44734826-421AC159-4ECB-4B7B-83D8-C5172BC7FC76Q45903627-9DD7C8B0-58C5-4B65-9A4A-0FADF3FA3586Q47954798-C19417DC-29F1-43B6-9186-D9274E4A1169Q51254235-981B3A5D-1BDE-404B-AC9A-EBD27CF93D0FQ52935931-4D84D3EB-49B0-4462-935F-09F0356E7B0FQ54290272-0F419AEC-00EA-4941-80FA-088B854C539EQ57767895-8C6AAE7C-8324-430B-B53E-A9FE245F5AD5Q57767898-CEF64BF5-F385-485D-90DE-C418E1D16DF8Q57767907-7CE10622-6E31-488B-8B1F-757F96F828A1Q57767909-495F2FC0-A0AF-47BF-92D5-ACE402492094Q57767923-C788326A-848F-414F-9D65-7E3CDE81409DQ57767926-AC79E128-9BD5-4638-8F43-4BF828901E86Q57767930-5DCD877F-822B-4A7D-8757-37F1D8863C26Q57767937-DACD0425-E1C9-4D93-8B00-0F47E3C73396Q57767943-B9C45559-8B6B-4C06-AC2B-A2BFC8F37D32Q57767958-AAB7885C-84B7-4279-9F44-3379D5B48E2EQ57767985-0B1CB095-BC99-41CC-8FA3-21A59EDA1061Q57767987-03F0B204-6A1A-4BB5-A357-BF1EB95D3516Q86869272-F80D445A-49A6-4680-ADAD-176EE955E897Q89051877-0D4DAD7A-8B22-4FF0-824E-20BFCE4FA6CCQ89062860-C4232177-28CC-4C26-A23F-876EF6556A40Q92596861-352CD55A-F33E-43C6-AD26-60DE0BF36394
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marina Mesquida
@ast
Marina Mesquida
@en
Marina Mesquida
@es
Marina Mesquida
@nl
Marina Mesquida
@pt
type
label
Marina Mesquida
@ast
Marina Mesquida
@en
Marina Mesquida
@es
Marina Mesquida
@nl
Marina Mesquida
@pt
prefLabel
Marina Mesquida
@ast
Marina Mesquida
@en
Marina Mesquida
@es
Marina Mesquida
@nl
Marina Mesquida
@pt
P106
P1153
36128734800
P21
P31
P496
0000-0003-0270-0978